Moderna MRNA Stock
Moderna Price Chart
Moderna MRNA Financial and Trading Overview
| Moderna stock price | 49.06 USD |
| Previous Close | 47.19 USD |
| Open | 47.07 USD |
| Bid | 43.69 USD x 100 |
| Ask | 48.6 USD x 100 |
| Day's Range | 44.2 - 47.07 USD |
| 52 Week Range | 22.28 - 59.55 USD |
| Volume | 4.4M USD |
| Avg. Volume | 7.38M USD |
| Market Cap | 18.32B USD |
| Beta (5Y Monthly) | 1.056 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.14 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.2 USD |
MRNA Valuation Measures
| Enterprise Value | 14.82B USD |
| Trailing P/E | N/A |
| Forward P/E | -10.983012 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 8.23443 |
| Price/Book (mrq) | 2.1032612 |
| Enterprise Value/Revenue | 6.659 |
| Enterprise Value/EBITDA | -6.445 |
Trading Information
Moderna Stock Price History
| Beta (5Y Monthly) | 1.056 |
| 52-Week Change | 74.45% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 59.55 USD |
| 52 Week Low | 22.28 USD |
| 50-Day Moving Average | 50.17 USD |
| 200-Day Moving Average | 37.48 USD |
MRNA Share Statistics
| Avg. Volume (3 month) | 7.38M USD |
| Avg. Daily Volume (10-Days) | 5.01M USD |
| Shares Outstanding | 396.79M |
| Float | 370.1M |
| Short Ratio | 7.25 |
| % Held by Insiders | 7.30% |
| % Held by Institutions | 78.83% |
| Shares Short | 58.07M |
| Short % of Float | 17.89% |
| Short % of Shares Outstanding | 14.64% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -143.55% |
| Operating Margin (ttm) | -131.10% |
| Gross Margin | -69.88% |
| EBITDA Margin | -103.32% |
Management Effectiveness
| Return on Assets (ttm) | -13.092% |
| Return on Equity (ttm) | -36.55% |
Income Statement
| Revenue (ttm) | 2.22B USD |
| Revenue Per Share (ttm) | 5.69 USD |
| Quarterly Revenue Growth (yoy) | 260.19% |
| Gross Profit (ttm) | -1555000064 USD |
| EBITDA | -2299000064 USD |
| Net Income Avi to Common (ttm) | -3193999872 USD |
| Diluted EPS (ttm) | -8.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.21B USD |
| Total Cash Per Share (mrq) | 13.12 USD |
| Total Debt (mrq) | 1.3B USD |
| Total Debt/Equity (mrq) | 17.52 USD |
| Current Ratio (mrq) | 2.409 |
| Book Value Per Share (mrq) | 21.954 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1466000000 USD |
| Levered Free Cash Flow (ttm) | -20000000 USD |
Profile of Moderna
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 325 Binney Street |
| ZIP | 02142 |
| Phone | 617 714 6500 |
| Website | https://www.modernatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4700 |
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Q&A For Moderna Stock
What is a current MRNA stock price?
Moderna MRNA stock price today per share is 49.06 USD.
How to purchase Moderna stock?
You can buy MRNA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Moderna?
The stock symbol or ticker of Moderna is MRNA.
Which industry does the Moderna company belong to?
The Moderna industry is Biotechnology.
How many shares does Moderna have in circulation?
The max supply of Moderna shares is 396.79M.
What is Moderna Price to Earnings Ratio (PE Ratio)?
Moderna PE Ratio is now.
What was Moderna earnings per share over the trailing 12 months (TTM)?
Moderna EPS is -8.14 USD over the trailing 12 months.
Which sector does the Moderna company belong to?
The Moderna sector is Healthcare.
Moderna MRNA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| S&P 500 INDEX SPX | 7553.68 USD — |
-0.74
|
3.46B USD — | — — | — — | — - | 3.46B USD — |
| S&P 500 (Yahoo.com) GSPC | 7553.68 USD — |
-0.74
|
3.41B USD — | 7551.22 USD — | 7605.35 USD — | — - | 3.41B USD — |
| US100 NDX | 30571.24 USD — |
-0.29
|
1.47B USD — | 30441.81 USD — | 30762.2 USD — | — - | 1.47B USD — |
| US Tech-100 ESG Net Notional Tot NDXESG24 | 2389.66 EUR 2612.22 USD |
-0.14
|
— — | 2382.94 EUR 2604.88 USD | 2409.43 EUR 2633.83 USD | — - | — — |
| US Tech-100 Equal Weighted NDXE | 10277.15 USD — |
-0.12
|
— — | 10192.96 USD — | 10302.69 USD — | — - | — — |
| US Tech-100 Notional Net Return XNDXNNREUR | 5505.79 EUR 6018.57 USD |
-0.02
|
— — | 5486.95 EUR 5997.98 USD | 5543.89 EUR 6060.23 USD | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech-100 Micro Index XND | 305.71 USD — |
-0.29
|
— — | 304.42 USD — | 307.62 USD — | — - | — — |
| Stlmt ID US Tech 100 XQO | 16266.86 USD — |
-0.45
|
— — | 15738.2 USD — | 16639.8 USD — | — - | — — |
| US Tech-100 Pre Market Indicator QMI | 30699.94 USD — |
+0.13
|
— — | 30671.39 USD — | 30758.24 USD — | — - | — — |
| US Tech-100 Reduced Value Index NQX | 6114.25 USD — |
-0.29
|
— — | 6088.41 USD — | 6152.33 USD — | — - | — — |
| US Tech Global BuyBack Achievers DRBG | 2937.45 USD — |
-0.42
|
— — | 2933.21 USD — | 2938.03 USD — | — - | — — |
| US Tech US Price Setters Index NQPRCE | 2899.6 USD — |
-0.61
|
— — | 2899.37 USD — | 2909.46 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 4054.02 USD — |
-0.25
|
— — | 4019.75 USD — | 4077 USD — | — - | — — |
| US Tech-100 Ex-Tech Sector NDXX | 5832.96 USD — |
-0.28
|
— — | 5822.81 USD — | 5854.41 USD — | — - | — — |
| US Tech-100 ESG JPY Index NDXESG07 | 3307.99 JPY 22.33 USD |
-0.37
|
— — | 3296.39 JPY 22.25 USD | 3333.18 JPY 22.5 USD | — - | — — |
| US Tech-100 PM Settlement Value XQC | 16331.98 USD — |
+1.13
|
— — | 16331.98 USD — | 16331.98 USD — | — - | — — |
| US Tech-100 Notional Net Total R XNDXNNR | 35590.81 USD — |
-0.29
|
— — | 35440.2 USD — | 35813.12 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
- {{ link.label }} {{link}}